| Willie Quon, MD | |
|
1400 S Dobson Rd, Mesa, AZ 85202-4707 | |
| (480) 835-3000 | |
| Not Available |
| Full Name | Willie Quon |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 30 Years |
| Location | 1400 S Dobson Rd, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780678359 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 23989 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Valleywise Health Medical Center | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| District Medical Group Inc | 7315086691 | 356 |
News Archive
A University of Illinois Chicago team has been awarded over $4 million to establish a research center focusing on the health and function of people with serious mental illness.
Phosphate Therapeutics Limited, a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD).
Health reform can be assessed from the perspective of four groups that collectively include most Americans. For those who are now in Medicaid or who are uninsured, reform will be a major gain. For those who obtain health insurance in the individual and small-group markets, reform should bring improvements. For those who have health insurance from midsize- and large-group insurers, reform will bring little change. Finally, for Medicare beneficiaries, reform promises to bring positive change.
Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I clinical trials by Merck & Co. Inc. Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.
› Verified 8 days ago
| Entity Name | Canyon State Anesthesiologists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265439525 PECOS PAC ID: 8628069986 Enrollment ID: O20040524001249 |
News Archive
A University of Illinois Chicago team has been awarded over $4 million to establish a research center focusing on the health and function of people with serious mental illness.
Phosphate Therapeutics Limited, a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD).
Health reform can be assessed from the perspective of four groups that collectively include most Americans. For those who are now in Medicaid or who are uninsured, reform will be a major gain. For those who obtain health insurance in the individual and small-group markets, reform should bring improvements. For those who have health insurance from midsize- and large-group insurers, reform will bring little change. Finally, for Medicare beneficiaries, reform promises to bring positive change.
Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I clinical trials by Merck & Co. Inc. Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.
› Verified 8 days ago
| Entity Name | District Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336472448 PECOS PAC ID: 7315086691 Enrollment ID: O20091125000583 |
News Archive
A University of Illinois Chicago team has been awarded over $4 million to establish a research center focusing on the health and function of people with serious mental illness.
Phosphate Therapeutics Limited, a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD).
Health reform can be assessed from the perspective of four groups that collectively include most Americans. For those who are now in Medicaid or who are uninsured, reform will be a major gain. For those who obtain health insurance in the individual and small-group markets, reform should bring improvements. For those who have health insurance from midsize- and large-group insurers, reform will bring little change. Finally, for Medicare beneficiaries, reform promises to bring positive change.
Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I clinical trials by Merck & Co. Inc. Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Willie Quon, MD Po Box 29211, Phoenix, AZ 85038-9211 Ph: (602) 273-6770 | Willie Quon, MD 1400 S Dobson Rd, Mesa, AZ 85202-4707 Ph: (480) 835-3000 |
News Archive
A University of Illinois Chicago team has been awarded over $4 million to establish a research center focusing on the health and function of people with serious mental illness.
Phosphate Therapeutics Limited, a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD).
Health reform can be assessed from the perspective of four groups that collectively include most Americans. For those who are now in Medicaid or who are uninsured, reform will be a major gain. For those who obtain health insurance in the individual and small-group markets, reform should bring improvements. For those who have health insurance from midsize- and large-group insurers, reform will bring little change. Finally, for Medicare beneficiaries, reform promises to bring positive change.
Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I clinical trials by Merck & Co. Inc. Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.
› Verified 8 days ago
Dr. John G Meernik, M D Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6247 E. Main Street, Suite 8, Mesa, AZ 85205 Phone: 480-981-9151 Fax: 480-981-0527 | |
Mark Murphy, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1400 S Dobson Rd, Mesa, AZ 85202 Phone: 480-835-3000 | |
Dr. Mikulkumar D Shah, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6644 E Baywood Ave, Mesa, AZ 85206 Phone: 480-321-2000 | |
Timothy E Black, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1500 S Dobson Road, Suite 203, Mesa, AZ 85202 Phone: 480-844-7100 Fax: 480-512-5486 | |
Joseph M Levine, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1500 S Dobson Rd, Ste 203, Mesa, AZ 85202 Phone: 480-844-7100 Fax: 480-512-5486 | |
Robert Thomas, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1400 S Dobson Rd, Mesa, AZ 85202 Phone: 480-272-8411 Fax: 480-361-1435 | |
Todd G Peterson, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6247 E. Main Street, Suite 8, Mesa, AZ 85205 Phone: 480-981-9151 Fax: 480-981-0527 |